Braun 1990.

Methods	DESIGN Description: random‐assignment, placebo‐controlled, crossover, 2 week titrated placebo washout, flexible dose, double‐blind, single centre BLINDING Participants: Unclear Assessors: Yes Administrators: Unclear ALLOCATION CONCEALMENT Method: Unclear RANDOMISATION Method: Unclear
Participants	SAMPLE Description: 16 DSM‐III PTSD, 25% combat‐veterans, mean age: 37.7 years (19‐56), 13% (2/16) MDD, described as chronic and treatment‐refractory SCREENING Primary diagnosis: Unclear Comorbidity: None
Interventions	Description: alprazolam 1.5mg to 6 mg/d (max avg: 4.65 mg/d) in divided doses vs placebo x 5 weeks each phase of crossover
Outcomes	Outcomes: DSM based PTSD scale, IES, HAM‐D, HAM‐A, Visual Analogue (not clear which outcomes are secondary or primary). Data estimation: Observed cases for patients who completed 5 weeks of both phases
Notes	INDUSTRY SUPPORT Industry funded: Unclear Medication provided by industry: Unclear Any of the authors work for industry: Unclear ADDITIONAL INFORMATION Drop‐out rates: 3/7 (43%) on alprazolam, 3/9 (33%) on placebo. Quality Rating Scale score: 14
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear